Myriad(MYGN) - 2025 Q1 - Quarterly Results

Exhibit 99.1 1 Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights SALT LAKE CITY, May 6, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its first quarter ended March 31, 2025 and updated its previously issued financial guidance on business performance for the full-year 2025. "We had a challenging first quarter of 2025 with strength in our prenatal and onc ...